Terns Pharmaceuticals, Inc. EBT margin

EBT margin of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBT margin growth rates and interactive chart. The Earnings before tax margin. Calculated as earnings before tax divided by revenue. Measures the profitability of a company after all expenses are paid but before taxes. This is useful to compare various companies in an industry that might have different tax regimes or tax rates.


Highlights and Quick Summary

  • EBT margin for the quarter ending March 31, 2022 was 0.0% (a -100.0% decrease compared to previous quarter)
  • Year-over-year quarterly EBT margin decreased by NaN%
  • Annual EBT margin for 2021 was -4965.0% (a -Infinity% decrease from previous year)
  • Annual EBT margin for 2020 was 0.0% (a NaN% decrease from previous year)
  • Annual EBT margin for 2019 was 0.0% (a NaN% decrease from previous year)
  • Twelve month EBT margin ending March 31, 2022 was 0.0% (a NaN% decrease compared to previous quarter)
  • Twelve month trailing EBT margin decreased by NaN% year-over-year
Trailing EBT margin for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
0.0% 0.0% 0.0% 0.0%
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBT margin of Terns Pharmaceuticals, Inc.

Most recent EBT marginof TERN including historical data for past 10 years.

Interactive Chart of EBT margin of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. EBT margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 0.0%
2021 -1381.3% 0.0% 0.0% 0.0% -4965.0%
2020 0.0% 0.0% 0.0% 0.0% 0.0%
2019 0.0% 0.0%
2018 0.0%

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.